MultiCell Technologies (OTCPK:MCET) - Stock Price, News & Analysis

MCET Stock Overview

A biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. More details

MCET fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

Does not have a meaningful market cap ($5K)

Shares are highly illiquid

MultiCell Technologies, Inc. Competitors

Genocea Biosciences

OTCPK:GNCA.Q

US$5.9k

ObsEva

OTCPK:OBSE.F

US$117.0

Vaxxinity

OTCPK:VAXX

US$12.7k

eFFECTOR Therapeutics

OTCPK:EFTR

US$940.0

Price History & Performance

Summary of all time highs, changes and price drops for MultiCell Technologies
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.0005
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	0%
33 Year Change	0%
5 Year Change	-99.00%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	MCET	US Biotechs	US Market
7D	0%	2.4%	0.5%
1Y	0%	15.6%	30.7%

Return vs Industry: MCET underperformed the US Biotechs industry which returned 18.8% over the past year.

Return vs Market: MCET underperformed the US Market which returned 32.3% over the past year.

Price Volatility

Is MCET's price volatile compared to industry and market?
MCET volatility
MCET Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: MCET's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine MCET's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1962	n/a	Jerry Newmin	n/a

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications.

MultiCell Technologies, Inc. Fundamentals Summary

How do MultiCell Technologies's earnings and revenue compare to its market cap?
MCET fundamental statistics
Market cap	US$5.00k
Earnings (TTM)	-US$253.60k
Revenue (TTM)	US$805.24k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is MCET overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MCET income statement (TTM)
Revenue	US$805.24k
Cost of Revenue	US$216.92k
Gross Profit	US$588.31k
Other Expenses	US$841.92k
Earnings	-US$253.60k

Last Reported Earnings

Aug 31, 2015

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did MCET perform over the long term?

See historical performance and comparison